Physician profile
John Brian Jasper
NPI 1134548258
$2,542.26
in general payments reported to CMS, 2019-2025
27 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $36.00 · 2021: $77.80 · 2022: $196 · 2023: $665 · 2024: $756 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $400.25 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $348.30 | 2023-2025 | |
| Novo Nordisk INC | $335.97 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $274.87 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $199.49 | 2022-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.06 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $98.80 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $83.85 | 2022-2023 | |
| Corium, LLC | $65.91 | 2023 | Adlarity |
| Novartis Pharmaceuticals Corporation | $61.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.62 | 2020-2025 | Eliquis |
| Averitas Pharma INC. | $54.22 | 2025 | Qutenza |
| Exact Sciences Corporation | $49.50 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $46.86 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $43.21 | 2023-2024 | Ultomiris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $37.82 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbvie INC. | $32.78 | 2021 | |
| Astellas Pharma US INC | $29.48 | 2023-2024 | Veozah |
| Abbott Laboratories | $28.87 | 2019-2022 | |
| Insulet Corporation | $24.42 | 2025 | Omnipod |
| Eisai INC. | $22.60 | 2025 | |
| Allergan, INC. | $19.46 | 2020 | |
| Medtronic, INC. | $18.02 | 2023 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $15.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.22 | 2022 | |
| Medtronic Vascular, INC. | $14.42 | 2019 | |
| Merck Sharp & Dohme LLC | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.